2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults (JACC April 2026-1)-Article: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults

Pdf Summary

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline provides a comprehensive, evidence-based approach to evaluating, managing, and following adults (≥18 years) with acute pulmonary embolism (PE), spanning symptom onset through post-discharge care. A central innovation is the AHA/ACC <strong>Acute Pulmonary Embolism Clinical Categories (A–E)</strong>, designed to improve severity classification, prognosis, and treatment selection by integrating clinical severity scores, hemodynamics, respiratory status, biomarkers, and right ventricular (RV) imaging. Category A covers incidental/asymptomatic PE; B symptomatic low-risk; C symptomatic with elevated severity scores (with/without biomarker/RV abnormalities); D incipient cardiopulmonary failure (including “normotensive shock” concepts); and E cardiopulmonary failure with persistent hypotension, refractory shock, or arrest. A respiratory modifier (“R”) captures prominent hypoxemia/ventilatory support needs.

For diagnosis, the guideline emphasizes structured pretest probability assessment (e.g., Wells, Geneva, PERC) and <strong>D-dimer strategies</strong> (age-adjusted thresholds; YEARS, including pregnancy-adapted YEARS) to safely reduce unnecessary imaging. When imaging is indicated, <strong>CT pulmonary angiography (CTPA)</strong> is preferred over V/Q scanning for confirmation; V/Q SPECT is favored over planar V/Q when used. Echocardiography is <strong>not</strong> recommended to diagnose PE but is important for RV risk stratification and should include standardized RV metrics; CTPA reports should include numeric RV/LV ratio.

Management centers on prompt <strong>anticoagulation</strong>: LMWH is recommended over UFH when parenteral therapy is needed, and DOACs are recommended over warfarin when eligible. Outpatient treatment or early discharge is reasonable for Category A/B patients with appropriate decision tools and reliable follow-up. <strong>PERT teams</strong> are recommended to improve timeliness and coordination, especially for higher-risk PE. Advanced therapies (systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy, surgical embolectomy, ECMO) are mainly reserved for the highest-risk categories, balancing benefit against bleeding risk. IVC filters are limited to patients who cannot receive anticoagulation, with retrievable filters and structured retrieval plans emphasized.

Follow-up includes early post-discharge contact (within ~1 week), reassessment by ≤3 months for anticoagulation duration, and symptom screening for at least 1 year to detect chronic thromboembolic pulmonary disease and other sequelae.

Meta Tag

Concept Pulmonary Embolism

Concept Acute Pulmonary Embolism

Concept Risk Stratification

Concept Anticoagulation

Concept Severity

Keywords

2026 AHA ACC pulmonary embolism guideline

acute pulmonary embolism clinical categories A–E

risk stratification hemodynamics biomarkers RV imaging

Wells Geneva PERC pretest probability

D-dimer age-adjusted YEARS pregnancy-adapted YEARS

CT pulmonary angiography CTPA vs V/Q SPECT

right ventricular dysfunction RV/LV ratio echocardiography metrics

anticoagulation DOACs vs warfarin LMWH vs UFH

pulmonary embolism response team PERT

advanced PE therapies thrombolysis thrombectomy embolectomy ECMO IVC filter retrieval follow-up

Pulmonary Embolism

Acute Pulmonary Embolism

Risk Stratification

Anticoagulation

Severity